|
|
| | H-Leu-Ser-Lys-Leu-NH2 Basic information |
| | H-Leu-Ser-Lys-Leu-NH2 Chemical Properties |
| Boiling point | 817.8±65.0 °C(Predicted) | | density | 1.143±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | DMSO : ≥ 100 mg/mL (218.05 mM) | | pka | 13.40±0.46(Predicted) | | form | Solid | | color | White to off-white | | Sequence | H-Leu-Ser-Lys-Leu-NH2 |
| | H-Leu-Ser-Lys-Leu-NH2 Usage And Synthesis |
| Uses | L-Leucyl-L-seryl-L-lysyl-L-leucinamide can be useful in the study of relative contributions of core protein and solvation shell in terahertz dielectric properties of protein solutions. | | in vivo | LSKL, Inhibitor of Thrombospondin (TSP-1) (1 mg/kg; intraperitoneal injection; male Sprague-Dawley rats) is protective against subarachnoid fibrosis, attenuates ventriculomegaly and effectively suppresses hydrocephalus. LSKL, Inhibitor of Thrombospondin (TSP-1) treatment inhibits TGF-β1 activity and subsequent Smad2/3 signaling[1].
LSKL, Inhibitor of Thrombospondin (TSP-1) (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL, Inhibitor of Thrombospondin (TSP-1) successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL, Inhibitor of Thrombospondin (TSP-1) accelerates hepatocyte proliferation after hepatectomy[3]. | Animal Model: | 103 male Sprague-Dawley rats (6 weeks of age; 160-180 g) with subarachnoid hemorrhage (SAH)[1] | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Was protective against subarachnoid fibrosis, attenuated ventriculomegaly and effectively suppressed hydrocephalus.
|
|
| | H-Leu-Ser-Lys-Leu-NH2 Preparation Products And Raw materials |
|